Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target
May 12, 2020
By Amber Tong
Early collaborations with big-name partners lent Skyhawk Therapeutics both the endorsements and the capital to pursue a small molecule platform for drugging RNA, including pharma giant Merck.
Now Merck is coming back for its own round two, adding autoimmune and metabolic diseases to the menu.
As in the original deal, Merck isn’t breaking down the upfront, sticking to the $600 million per program figure to illustrate their interest here. Licenses to any IP arising from the collaboration goes to Merck, which would take over development once it exercises an option.
Full article can be found here